{"id":24760,"date":"2022-09-19T20:17:51","date_gmt":"2022-09-20T00:17:51","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=24760"},"modified":"2024-03-19T15:20:00","modified_gmt":"2024-03-19T19:20:00","slug":"david-r-glass-phd","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/david-r-glass-phd","title":{"rendered":"David R. Glass, PhD"},"content":{"rendered":"\n<p>Cutaneous T cell lymphoma (CTCL) is a skin cancer with limited treatments and poor survival rates. Anti-PD-1 and interferon-gamma (IFNg) mono- and combination therapies have shown some efficacy for some patients with advanced CTCL, but the unique immunological consequences of giving an immune-activating drug to patients with a mature T cell-derived cancer are unknown. Here, I am applying a holistic, multi-omic, systems immunology approach to investigate the endogenous and neoplastic immune response in CTCL patients receiving either anti-PD-1 monotherapy or anti-PD-1 and IFNg combination therapy. I aim to characterize the systemic, local, and cellular responses to these therapies to better understand the successes and failures of these two clinical trials, as well as to identify predictive biomarkers of success and new therapeutic targets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Comprehensive immune profiling of cutaneous T cell lymphoma patients undergoing mono- or combination anti-PD-1 therapy<\/h3>\n\n\n\n<p>Fred Hutchinson Cancer Research Center | Skin Cancer | 2021 | Evan Newell, PhD<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cutaneous T cell lymphoma (CTCL) is a skin cancer with limited treatments and poor survival rates. Anti-PD-1 and interferon-gamma (IFNg) mono- and combination therapies have shown some efficacy for some patients with [&hellip;]<\/p>\n","protected":false},"featured_media":2379,"template":"","tax_cancer_type":[355,348],"tax_grant_type":[486],"tax_award_year":[478],"tax_institutions":[534],"tax_location_states":[497],"class_list":["post-24760","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"Postdoctoral Fellow","quote":"","scientist_last_name":"Glass","show_on_landing":true,"scientist_publish_until":"20250331"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>David R. Glass, PhD<\/title>\n<meta name=\"description\" content=\"Dr. Glass is applying a new DNA-sequencing technology to T cells from NPC patients undergoing checkpoint blockade.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"David R. Glass, PhD\" \/>\n<meta property=\"og:description\" content=\"Dr. Glass is applying a new DNA-sequencing technology to T cells from NPC patients undergoing checkpoint blockade.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-19T19:20:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd\",\"name\":\"David R. Glass, PhD\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png\",\"datePublished\":\"2022-09-20T00:17:51+00:00\",\"dateModified\":\"2024-03-19T19:20:00+00:00\",\"description\":\"Dr. Glass is applying a new DNA-sequencing technology to T cells from NPC patients undergoing checkpoint blockade.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png\",\"width\":400,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"David R. Glass, PhD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"David R. Glass, PhD","description":"Dr. Glass is applying a new DNA-sequencing technology to T cells from NPC patients undergoing checkpoint blockade.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd","og_locale":"es_ES","og_type":"article","og_title":"David R. Glass, PhD","og_description":"Dr. Glass is applying a new DNA-sequencing technology to T cells from NPC patients undergoing checkpoint blockade.","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd","og_site_name":"Cancer Research Institute","article_modified_time":"2024-03-19T19:20:00+00:00","og_image":[{"width":400,"height":400,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd","name":"David R. Glass, PhD","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png","datePublished":"2022-09-20T00:17:51+00:00","dateModified":"2024-03-19T19:20:00+00:00","description":"Dr. Glass is applying a new DNA-sequencing technology to T cells from NPC patients undergoing checkpoint blockade.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png","width":400,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/david-r-glass-phd#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"David R. Glass, PhD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/46221cfa-2b53-4e45-979a-ae83e3986e21.png","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/24760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/2379"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=24760"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=24760"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=24760"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=24760"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=24760"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=24760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}